Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Shirin Khambata"'
PDF file - 77K, List of Markers and Corresponding Affymetrix Probesets.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1194a6861fa689c619e3786194ff0029
https://doi.org/10.1158/1078-0432.22444613
https://doi.org/10.1158/1078-0432.22444613
Autor:
Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186537 (2017)
[This corrects the article DOI: 10.1371/journal.pone.0183023.].
Externí odkaz:
https://doaj.org/article/aac2a7a936aa4d6da4c43646e1a60f55
Autor:
Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183023 (2017)
For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Auto
Externí odkaz:
https://doaj.org/article/c3112e94142445b1a6c4dd435cc46f49
Autor:
Marius Ilie, Jonathan Juco, Véronique Hofman, Lingkang Huang, Paul Hofman, Shirin Khambata-Ford
Publikováno v:
Cancer Cytopathology. 126:264-274
BACKGROUND Pembrolizumab monotherapy is a standard-of-care treatment for the first- and second-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) values ≥ 50% and ≥ 1%, respec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d84b1819a2e726664f9358f867b2d3a5
https://doi.org/10.1002/cncy.21977
https://doi.org/10.1002/cncy.21977
Publikováno v:
Personalized medicine. 8(2)
The anti-EGF receptor monoclonal antibody cetuximab provides a case study for the development of predictive biomarkers in oncology. The identification and validation of KRAS mutation status as a predictor of lack of benefit from cetuximab in metastat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe785690eae35d58cb38f85adea6dae
https://pubmed.ncbi.nlm.nih.gov/29783412
https://pubmed.ncbi.nlm.nih.gov/29783412
Autor:
Marius, Ilie, Jonathan, Juco, Lingkang, Huang, Veronique, Hofman, Shirin, Khambata-Ford, Paul, Hofman
Publikováno v:
Cancer cytopathology. 126(4)
Pembrolizumab monotherapy is a standard-of-care treatment for the first- and second-line treatment of advanced non-small cell lung cancer with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) values ≥ 50% and ≥ 1%, respectively. PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::53fb411bb7b01aa5341c1dc8de5775b4
https://pubmed.ncbi.nlm.nih.gov/29411536
https://pubmed.ncbi.nlm.nih.gov/29411536
Autor:
Lingkang Huang, Shirin Khambata-Ford, Véronique Hofman, Christiane Copie-Bergman, Paul Hofman, Jonathan Juco, Marius Ilie
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183023 (2017)
PLoS ONE
PLoS ONE
Background For non–small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95ce27c2720b19c961ca61b0dc5012d0
http://europepmc.org/articles/PMC5552229?pdf=render
http://europepmc.org/articles/PMC5552229?pdf=render
Autor:
Ovidiu C. Trifan, Christopher T. Harbison, Shao-Chun Chang, George Green, Paul Ravetto, Christopher J. O'Callaghan, Christine Horak, Nancy Gustafson, Christos S. Karapetis, Daniel P. Malone, Pralay Mukhopadhyay, Derek J. Jonker, Shirin Khambata-Ford, Jean-Marie Ledeine
Publikováno v:
Archives of Pathology & Laboratory Medicine. 137:820-827
The therascreen KRAS RGQ polymerase chain reaction kit is being developed as a companion diagnostic to aid clinicians, through detection of KRAS mutations, in the identification of patients with metastatic colorectal cancer (mCRC) who are more likely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe53c720f4045c61e94f92b64143a6d
https://doi.org/10.5858/arpa.2012-0367-oa
https://doi.org/10.5858/arpa.2012-0367-oa
Autor:
Monique A. Franc, Ekopimo Ibia, Scott D. Patterson, Brian B Spear, Eileen Emison, William Brian, Rizwana Sproule, Michael R Bristow, Anahita Bhathena, Nadine Cohen, Chris B. Russell, Maha Karnoub, Amelia Wall Warner, Dai Wang, Peter M. Shaw, Diane M. Barnes, Shirin Khambata-Ford, Peggy H. Wong, Amir Snapir, Sharada Louis Truter, Agnes Westelinck
Publikováno v:
Pharmacogenomics. 12:939-951
One approach to delivering cost-effective healthcare requires the identification of patients as individuals or subpopulations that are more likely to respond to an appropriate dose and/or schedule of a therapeutic agent, or as subpopulations that are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5565234eb2b80a3ce0b3c632cb16f1c
https://doi.org/10.2217/pgs.11.52
https://doi.org/10.2217/pgs.11.52
Autor:
Shak S, David J. Mauro, Christopher T. Harbison, Maddala T, Shirin Khambata-Ford, Rowinsky Ek, Li-An Xu, Baker Jb, D. Dutta, Watson D, Munneke Bm, Edwin A. Clark
Publikováno v:
British Journal of Cancer
Background: Although it is accepted that metastatic colorectal cancers (mCRCs) that carry activating mutations in KRAS are unresponsive to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, a significant fraction of KRAS wild-type (w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64e075f17a43a30e1c99e9ab7c90856a
https://doi.org/10.1038/sj.bjc.6606054
https://doi.org/10.1038/sj.bjc.6606054